Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

Core Viewpoint - Agenus Inc. has successfully closed a strategic collaboration with Zydus Lifesciences Ltd to enhance the development and commercialization of its immunotherapy combination program involving botensilimab and balstilimab [1] Group 1: Collaboration Details - The agreement aims to accelerate global development and potential commercialization of the BOT+BAL immunotherapy combination program [1] - The collaboration provides Agenus with strategic capital and long-term biologics manufacturing capacity [1]